Abstract Lysophosphatidylcholine (LysoPtdCho) levels are elevated in sera in patients with atherosclerosis and in atherosclerotic tissue. Previous studies have shown that reactive chlorinating species attack plasmalogens in human coronary artery endothelial cells (HCAEC), forming lysoPtdCho and lysoPtdCho-chlorohydrin (lysoPtdChoClOH). The results herein demonstrate for the first time that lysoPtdCho-ClOH is elevated over 60-fold in human atherosclerotic lesions. In cultured HCAEC, 18:0 lysoPtdCho-ClOH led to a statistically significant increase in P-selectin cell-surface expression, but unlike 18:1 lysoPtdCho did not lead to cyclooxygenase-2 protein expression. These data show that 18:0 lysoPtdCho-ClOH is elevated in atherosclerotic tissue and may have unique pro-atherogenic properties compared to lysoPtdCho.
Introduction
Lysophosphatidylcholine (LysoPtdCho) is elevated in atherosclerotic lesions from monkey [1] , rat [2] , and human [3] and may be an important pro-atherogenic mediator. LysoPtdCho comes from a variety of sources including the enzymatic action of a variety of phospholipase A 2 s (PLA 2 ) on low-density lipoprotein (LDL) and membrane phosphatidylcholine (PtdCho) [4] . Numerous studies have shown that serum levels of lysoPtdCho are elevated from patients that have chronic inflammatory conditions such as renal failure on hemodialysis [5] , diabetes [6] , cancer [7] , asthma [8] , and atherosclerosis [9] .
Activated monocytes and a subpopulation of macrophages release myeloperoxidase (MPO), which is an enzyme that catalyzes the production of reactive chlorinating species (RCS) such as hypochlorous acid (HOCl) [10] . Levels of MPO are elevated in atherosclerotic plaques [11] , as well as MPO-derived oxidation products such as 3-chlorotyrosine [12] and 2-chlorohexadecanal (2-ClHDA) [3] . It has been shown that phosphatidylcholine-chlorohydrins (PtdCho-ClOHs) are produced from isolated LDL treated with physiologically-relevant concentrations of HOCl [13] . PtdCho-ClOHs have been shown to elicit ATP depletion and necrosis in HL60, U937, Jurkat, and THP-1 cells [14, 15] . Additionally, Dever et al. [15] demonstrated that 25-50 lM PtdCho-ClOHs increased leukocyte adhesion to mouse artery segments by P-selectin expression [16] and increased caspase-3 activity [15] . There are several classes of phospholipase A 2 (PLA 2 ) that function to release the sn-2 fatty acid chains from the glycerol backbone of PtdCho, thereby potentially releasing free fatty acid-chlorohydrins (FFA-ClOHs). FFA-ClOHs cause ATP depletion [15] and cell death of erythrocytes [17] and endothelial cells [18] . In particular, administration of linoleic acid monochlorohydrin elicited decreased muscle tension using an isolated guinea-pig heart papillary muscle preparation [6] .
Plasmalogens are a subclass of glycerophospholipids enriched in the cells of the cardiovascular system, and is thought to play an important role in normal heart function, as well as serve as an endogenous lipoprotein antioxidant [19] . Recently, our lab and others have shown that RCS attack of plasmenylcholine in liposomes and in human coronary artery endothelial cells (HCAEC) yields lysoPtdCho [20, 21] and lysoPtdCho-chlorohydrin (lysoPtdCho-ClOH) [21] [22] [23] . Additionally, we have shown that HOCl preferentially targets lysoPtdCho in comparison to PtdCho [22] . Since lysoPtdCho is elevated in atherosclerotic lesions and is preferentially targeted by RCS in vitro, the present study was designed to determine that lysoPtdCho-ClOH levels increase in atherosclerotic lesions. We show here, for the first time, that lysoPtdCho-ClOH is elevated in atherosclerotic lesions, and that lysoPtdCho-ClOH induces P-selectin cellsurface expression on HCAEC.
Materials and Methods

Lipids
Lysoplasmenylcholine (1-O-hexadec-1 0 -enyl-GPC) was prepared from bovine heart lecithin and purified as described previously [24] . 1-O-Hexadec-1 0 -enyl-2-heptadec-10 0 -enoyl-GPC (16:0-17:1 plasmenylcholine), 1-O-hexadec-1 0 -enyl-2-octadec-9 0 -enoyl-GPC (16:0-18:1 plasmenylcholine), and 1-O-hexadec-1 0 -enyl-2-nonadec-10 0 -enoyl-GPC (16:0-19:1 plasmenylcholine) were synthesized by an anhydrous reaction utilizing 1-O-hexadec-1 0 -enyl-GPC and heptadec-10 0 -enoyl chloride, octadec-9 0 -enoyl chloride, and nonadec-10 0 -enoyl chloride, respectively, as precursors and dimethylaminopyridine as a catalyst. 
Human Tissue
Atherosclerotic and normal aortic tissue was collected from human postmortem autopsy specimens as authorized by Saint Louis University Institutional Review Board Protocol #10014. In general, tissues were harvested 6-12 h postmortem and then were sequentially rinsed, and submerged in PBS supplemented with 100 lM diethylenetriaminepentaacetic acid and 100 lM butylhydroxytoluene, frozen in liquid N 2 , and stored at -80°C until analysis. Normal tissue was collected from subjects showing no overt indications of atherosclerotic vascular disease. Frozen tissue was weighed and then crushed in a liquid nitrogen-chilled mortar and pestle. Lipids and internal standards 17:0 and 19:0 lysoPtdCho-ClOH were added to the crushed tissue in methanol/chloroform/saline (2.5:1.5:1 v/v/v). After 5 min, chloroform was added resulting in a 1:1:0.8 methanol/ chloroform/saline ratio [28] . The extracted organic phase was stored in chloroform at -20°C under N 2 until analysis.
Electrospray Ionization-Tandem Mass Spectrometry
Lipid extracts were reconstituted in methanol containing 10 lM NaOH and analyzed by ESI-MS in the direct infusion mode at a flow rate of 1-3 lL/min using Thermo Electron TSQ Quantum Ultra instrumentation. The choline glycerophospholipids yield intense [M + Na] + adduct ions by electrospray ionization in the positive ion mode. Tandem mass spectrometry was performed on selected ions (collision energies were *32-38 eV). To detect lysoPtdCho and lysoPtdCho-molecular species, survey scan and neutral loss scanning of 95 amu (NL 95) was employed. Spectra were averaged at 3-5 min and processed utilizing Xcalibur software (Thermo), and molecular species were quantified by comparing the ion intensity of individual molecular species to that of the internal standards. The differences in 13 C isotope effects (Z 1 ) between the endogenous 16:0 and 18:0 lysoPtdCho-ClOH and the internal standards 17:0 and 19:0 lysoPtdCho-ClOH were corrected [29] .
P-selectin Surface Expression P-selectin expression on the surface of HCAEC was measured by a modified ELISA with nonpermeabilized monolayers using a modified version of the method described by Willam et al. [30] . HCAEC, grown to confluence in 24-well plates, were incubated with indicated lipids in Hanks' buffer for 5 min at 37°C in 95% O 2 /5% CO 2 . At the end of incubations, buffer was quickly removed and cells were immediately fixed with 1% paraformaldehyde overnight at 4°C. Cells were then washed 3 times with PBS and then blocked with Tris-buffered saline containing 0.1% Tween 20 (v/v) supplemented with 0.8% BSA (w/v) and 0.5% fish gelatin (w/v) for 1 h at 24°C. Primary goat polyclonal antibody (1:500) for P-selectin (Santa Cruz) was used before treatments with horseradish peroxidase-conjugated rabbit-anti-goat secondary antibody (1:5,000). Subsequently, each well was incubated in the dark with the 3,3 0 ,5,5 0 -tetramethylbenzidine liquid substrate system. Reactions were stopped by the addition of sulfuric acid, and color development was measured with a microtiter plate spectrophotometer (Wallac) at 450 nm [3] .
Western Blotting HCAEC monolayers in 60-mm 2 dishes were exposed to various experimental conditions in the presence of 2% FBS-supplemented EGM-2-MV. At the end of the treatment, the medium was aspirated from the dishes and monolayers were rinsed with PBS. Cells were scraped in SDS sample buffer containing DTT, boiled, and subjected to SDS-PAGE utilizing 10% polyacrylamide gels followed by transfer of proteins to polyvinylidene difluoride (PVDF)-plus membranes (GE Waters) for Western blot analysis. Blots were probed with an antibody to COX-2 (1:1,000) (Zymed) and an HRP-conjugated secondary antibody (1:7,000) (Sigma). Blots were stripped (0.1 M glycine, pH 2.5) and, following extensive washing, reprobed with an antibody to b-actin (1:5,000) (Abcam) and probed with an HRP-conjugated goat-anti-rabbit (1:7,000) (Sigma). Immunoreactive bands were visualized by exposure to autoradiographic film following incubation with enhanced chemiluminescence reagent (GE Healthcare).
Data Analysis
Data were normalized to the respective control mean values and are expressed as means ± SEM. Statistical analyses of data were performed by t-test and P B 0.05 was considered statistically significant.
Results
Lipid extracts from both atherosclerotic and normal human aorta samples were analyzed by ESI-MS. Previous studies have shown that unsaturated lysoPtdCho is present in higher levels of atherosclerotic lesions [3] and that MPO-derived oxidation products such as 3-chlorotyrosine [12] and the achlorofatty aldehyde, 2-ClHDA [3] , have been detected in lesions. Since MPO-derived RCS have been shown to attack lysoPtdCho to produce lysoPtdCho-ClOH [21] [22] [23] , ESI-MS was used to assess lysoPtdCho-ClOH accumulation in atherosclerotic lesions. Initial inspection of the spectra from normal and atherosclerotic tissue in the positive ion mode show noticeable differences, qualitatively revealing an increase in lysoPtdCho molecular species, which include m/ z 518, 542, 544, 546, and 566, corresponding to 16:0, 18:2, 18:1, 18:0, and 20:4 lysoPtdCho, respectively (Fig 1a) . Neutral loss scanning of 95 amu, which corresponds to the combined neutral loss of the trimethylamine and HCl [22] , was utilized to detect chlorinated choline glycerophospholipid species. Utilizing neutral loss scanning of 95 amu, the relative abundance of 18:0 and 16:0 lysoPtdCho-ClOH were compared to the relative intensities of the internal standards for quantification. Atherosclerotic tissue contains approximately 69-fold more 16:0 lysoPtdCho-ClOH and 82-fold more 18:0 lysoPtdCho-ClOH than normal tissue (Fig. 2) . However, 18:0 lysoPtdCho-ClOH is about 10.7-fold more abundant than 16:0 lysoPtdCho-ClOH. This likely reflects the abundance of 18:1 lysoPtdCho compared to 16:1 lysoPtdCho in atherosclerotic tissue (see Fig. 1a, spectra 2) . Other unsaturated lysoPtdCho molecular species, such as 18:2 and 20:4 lysoPtdCho (e.g., m/z 544 and 566, respectively), are elevated in atherosclerotic tissue compared to control tissue (Fig. 1a) . The accumulation of these unsaturated lysoPtdCho molecular species in atherosclerotic vascular tissue has previously been shown [3] , which likely reflect phospholipase A 1 or lipase activity directed at phosphatidylcholine or alternatively RCS attack of unsaturated plasmenylcholine molecular species [3] . It should be appreciated that lysoPtdCho molecular species containing multiple chlorohydrin residues were not observed in atherosclerotic tissue as well as in our previous in vitro studies [22] . These findings are similar to those of Panasenko et al. [31] who showed that multi-chlorohydrin species are unstable and degrade to short-chained lysoPtdCho molecular species.
Endothelial activation, and subsequent dysfunction, is recognized as a major hallmark in the development and progression of atherosclerosis [32] . LysoPtdCho induces a wide range of pro-atherogenic effects [33] , however the effects of lysoPtdCho-ClOHs are unknown. Two critical events in the development of atherosclerosis are cell-surface expression of proteins that tether blood monocytes to inflamed endothelium and release of chemotactic molecules [34] . Figure 3 shows that 10 lM 18:0 lysoPtdChoClOH elicits HCAEC surface expression of P-selectin at levels similar to that elicited by platelet activating factor [3] . The results suggest that lysoPtdCho-ClOH may function to recruit leukocytes to the endothelium by inducing an increase in coronary artery endothelial cell surface expression of P-selectin, an adhesion factor implicated in the development of vascular inflammation [35] .
Cyclooxygenase-2 (COX-2) is an inducible enzyme that catalyzes the production of prostaglandin H 2 (PGH 2 ) from phospholipid-derived arachidonic acid [36, 37] . COX-2 is highly expressed in atherosclerotic plaques [38] and increased COX-2 expression in endothelial cells has been shown to increase prostacyclin production [39] . Under normal conditions, prostacyclin has a variety of effects in the vasculature, including inhibiting platelet aggregation and adhesion, relaxing smooth muscle cells, and inhibiting leukocyte activation and adhesion [40] . Palmitoyl lysoPtdCho has been shown to induce COX-2 protein expression in vascular endothelial cells [41] [42] [43] . Our previous studies showed that unsaturated lysoPtdCho is elevated in human atherosclerotic plaques [3] . Robust COX-2 protein expression was elicited in HCAEC by 50 lM 18:1 lysoPtdCho, whereas only slight induction of COX-2 was seen following 50 lM 18:0 lysoPtdCho, and no COX-2 expression was observed after treatment with 18:0 lysoPtdCho-ClOH (Fig. 4) .
Discussion
Myeloperoxidase is found in human atherosclerotic lesions [11] and is localized in the shoulder regions of the plaque [44] . Products from MPO-derived RCS attack of tissue targets include, 3-chlorotyrosine, which is elevated sixfold in human atherosclerotic vascular tissue compared to normal vascular tissue [45] . Previous studies have shown that RCS attack of plasmenylcholine leads to the formation of unsaturated lysoPtdCho [20, 21] and a-chlorofatty aldehyde [46] (Scheme 1). Furthermore unsaturated lysoPtdCho is targeted by RCS leading to the production of lysoPtdCho-ClOH [21, 22] (Scheme 1). a-Chlorofatty aldehydes [3] , were the first chlorinated lipids found in atherosclerotic lesions and are elevated *1400-fold in atherosclerotic aorta. In this study, we utilized a soft ionization technique, ESI-MS/MS, and determined that human atherosclerotic tissue contains 69-fold more 16:0 and 82-fold more 18:0 lysoPtdCho-ClOH than normal tissue. Similar to our previous in vitro studies, only chlorohydrins derived from monoenoic lysoPtdCho molecular species were detected which likely reflects the instability of the lysoPtdCho chlorohydrins produced from polyunsaturated molecular species of lysoPtdCho [31] .
LysoPtdCho is elevated in atherosclerotic lesions [3] and in sera of people with atherosclerosis [9] . Interestingly the mechanism leading to the production of unsaturated molecular species of lysoPtdCho (e.g. 20:4 lysoPtdCho as observed as m/z 566 in Fig. 1a ) reflects a combination of activation of phospholipase A 1 lipase activities and RCS attack of plasmenylcholine molecular species. The results from this study demonstrate that 18:1 lysoPtdCho induces increased COX-2 protein expression in HCAEC. There are contradictory reports on the role of COX-2 in the development of atherosclerosis. Recent studies show that prostanoid synthases, such as those responsible for the synthesis of PGE 2 , PGD 2 , PGF 2 a, PGI 2 , and TXA, differentially couple with upstream COX-1 and COX-2 and that colocalization is essential for terminal prostanoid production. Prostanoid synthases preferentially localize to either COX isozyme, and some localize to both COX-1 and COX-2 depending on the stimulus [47] . It appears that the addition of a chlorohydrin moiety across the alkene bond led to the ablation of the robust increase in COX-2 protein induced by 18:1 lysoPtdCho in HCAEC. The elevation of 18:1 lysoPtdCho in atherosclerotic tissue may confer antiatherogenic properties in endothelial cells by increasing COX-2 protein expression and prostacyclin production. If this is the case, chlorohydrin formation of 18:1 lysoPtdCho due to RCS attack, leads to a molecular species that is unable to elicit COX-2 expression. If, however, 18:1 lysoPtdCho induces preferential coupling of pro-atherogenic PGE 2 or TXA to COX-2, further oxidation to 18:0 Previous studies have demonstrated that 2-ClHDA is a potent neutrophil chemoattractant, while unsaturated lysoPtdCho increases P-selectin surface expression on HCAEC [3, 20] . The results from this study show that 18:0 lysoPtdCho-ClOH also leads to increased P-selectin surface expression on HCAEC, which may function to recruit more MPO-containing leukocytes to sites of inflammation. RCS attack of plasmenylcholine may lead to the production of molecular species that lead to both leukocyte attraction and adhesion. Collectively these data suggest that lysoPtdCho-ClOH in injured blood vessels may propagate inflammation by facilitating leukocyte recruitment through a mechanism leading to P-selectin surface expression on endothelial cells.
Collectively the data presented herein show that lysoPtdCho-ClOH accumulate in human atherosclerotic tissue and have a potential role in the inflammatory state of the atherosclerotic lesion. It will be important in future studies to determine the accumulation and role of these lipids in early stages of atherosclerotic tissue as well as determine the tissue distribution of lysoPtdCho-ClOH at lesion sites as well as adjacent tissue. It will also be of great importance to determine that lysoPtdCho-ClOH are associated with oxidized LDL in the subintima. It would then follow that levels of 16:0 and 18:0 molecular species of lysoPtdCho-ClOH in blood LDL could potentially serve as a marker of coronary artery disease risk. It would be of interest as well to determine the choline glycerophospholipid, lysoPtdCho and lysoPtdCho-ClOH molecular species profile in diet-controlled studies comparing diets enriched in either monoenoic, saturated or cardioprotective x-3 fatty acids. Further studies on these novel chlorinated lipids as well as other blood-borne chlorinated lipids derived from MPO activity may prove to be important in the development of biomarkers for cardiovascular disease.
